A long regulatory path finally ended in success for Verrica Pharmaceuticals, Inc., which obtained US Food and Drug Administration approval for Ycanth (VP-102), the first drug cleared for the dermatological condition molluscum contagiosum. But the company’s 24 July announcement of a financing to bridge the early years of product launch did not sit well with investors.
The approval, late on 21 July, followed three FDA complete response letters since the West Chester, PA-based company first filed...
